OptimizeRx Corp Dossier - Source-backed chat

OptimizeRx Corp

OPRXNASDAQ

SectorHealth Care

IndustryHealth Care Technology

Beta (adjusted)1.03

Intrinsic Value $10.39median of 6 methods · middle span $5-$13based on filings through 30 Jun 2026

Market Price $8.39Price as of 1 Oct 2026

UndervaluedIntrinsic value is 24% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $158M

Enterprise Value $152.9M

Shares Outstanding 19.3M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

OptimizeRx Corp is navigating a transitional phase, shifting from traditional pharmaceutical marketing campaigns to a highly scalable, programmatic, and subscription-based model. While near-term headwinds from Most Favored Nation (MFN) pricing dynamics have pressured top-line growth—prompting a guidance cut to $95M–$100M for FY2026—the company's underlying operational leverage is expanding. This is evidenced by a massive Q1 2026 EPS beat ($0.14 non-GAAP vs. $0.01 consensus) and a significant reduction in interest expenses following a debt refinancing with Fifth Third Bank. The integration of its authenticated EHR network with major DSPs like DeepIntent unlocks a high-margin programmatic revenue channel that should drive long-term valuation recovery.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$12.40

High · most bullish analyst$18.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects prolonged disruption from MFN pricing dynamics and deeper cuts in marketing budgets by top-tier pharmaceutical manufacturers. Programmatic DSP integrations take longer to scale, leaving EHR inventory underutilized. Revenue falls below $90 million for FY2026, and high stock-based compensation continues to dilute retail investor sentiment, keeping the stock range-bound near its critical support levels.

Base CaseCentral scenario

The base case assumes OptimizeRx successfully stabilizes its core pharma accounts while scaling its programmatic EHR advertising network. Revenue for FY2026 lands within the guided range of $95M to $100M, and adjusted EBITDA reaches $21M to $25M. The transition to programmatic DSP integrations drives inventory utilization higher, offsetting MFN pricing pressures. Valuation multiples expand as recurring subscription revenue approaches 15% of the mix.

Bull CaseUpside scenario

The bull case rests on the successful transition of DAAP to a high-margin, recurring subscription model, which will improve revenue predictability and expand valuation multiples. Additionally, the programmatic expansion of its authenticated EHR network through DSP partnerships like DeepIntent opens up a massive, underutilized inventory channel (currently utilizing less than 10% of available inventory) to programmatic ad dollars, positioning the company for strong operating leverage and margin expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong operational leverage with non-GAAP EPS of $0.14 in Q1 2026, significantly beating consensus estimates despite a 10% YoY revenue decline.
Successful debt refinancing with Fifth Third Bank, lowering the interest rate by 625 basis points and generating approximately $1.5 million in annual interest savings.
Strategic expansion of platform capabilities by opening the proprietary EHR network to demand-side platforms (DSPs) like DeepIntent, unlocking a scalable programmatic revenue stream.
Implementation of cost-optimization initiatives expected to deliver $3 million in annualized savings ($1 million in 2026).

Key Investment Risks

Near-term revenue contraction and limited visibility due to Most Favored Nation (MFN) pricing dynamics and cautious spending by top-tier pharma clients.
High customer concentration, with a significant portion of revenue tied to the top 20 pharmaceutical manufacturers.
High stock-based compensation (representing a notable portion of operating expenses) which may weigh on GAAP profitability and investor sentiment.

Thesis Invalidation Triggers

FY2026 revenue falling below $90 million, indicating that MFN pricing pressures are more structural and enduring than anticipated.
Failure of the programmatic DSP integrations to generate meaningful revenue contribution by the end of 2026.
A significant deterioration in net revenue retention (NRR) below 100%.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.